BBC icon

Virtus LifeSci Biotech Clinical Trials ETF

16 hedge funds and large institutions have $1.99M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 4 closing their positions.

Holders
16
Holders Change
-3
Holders Change %
-15.79%
% of All Funds
0.26%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
Reduced
5
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Market Value Shares Shares
Change
Shares
Change %
Citadel Advisors
1
Citadel Advisors
Florida
$718K 32,763 +32,763 New
LPL Financial
2
LPL Financial
California
$412K 18,791 -1,533 -8%
Royal Bank of Canada
3
Royal Bank of Canada
Ontario, Canada
$408K 18,596 -22,501 -55%
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$233K 10,647 -25,137 -70%
Morgan Stanley
5
Morgan Stanley
New York
$123K 5,612 -800 -12%
US Bancorp
6
US Bancorp
Minnesota
$21.9K 1,000
FDCDDQ
7
Federation des caisses Desjardins du Quebec
Quebec, Canada
$18.4K 838
DSC
8
Duncker Streett & Co
Missouri
$16.5K 752
HI
9
Harbour Investments
Wisconsin
$16.2K 739
Osaic Holdings
10
Osaic Holdings
Arizona
$14.8K 674
GRP
11
Global Retirement Partners
California
$5.6K 233 -155 -40%
BWP
12
Baldwin Wealth Partners
Massachusetts
$2.19K 100
DF
13
DecisionPoint Financial
Arizona
$1.36K 62
BAM
14
Baldrige Asset Management
Pennsylvania
$1K 23
AF
15
Allworth Financial
California
$220 10
NA
16
NewEdge Advisors
Louisiana
$110 5
Goldman Sachs
17
Goldman Sachs
New York
-100,000 Closed
Rockefeller Capital Management
18
Rockefeller Capital Management
New York
-28,912 Closed
UBS Group
19
UBS Group
Switzerland
-3,290 Closed
MCC
20
Money Concepts Capital
Florida
-370 Closed
CFGS
21
Concourse Financial Group Securities
Alabama